Literature DB >> 15151211

Clusterin, a marker for anaplastic large cell lymphoma immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms.

Alessandra F Nascimento1, Jack L Pinkus, Geraldine S Pinkus.   

Abstract

We evaluated the immunohistochemical staining profile of clusterin in paraffin sections of 143 neoplasms (non-Hodgkin lymphoma, 83, including 41 anaplastic large cell lymphomas [ALCLs]; Hodgkin lymphoma, 17; primary and metastatic carcinoma, 30; and other neoplasms, 13). In 40 of 41 ALCLs (34 systemic, 7 cutaneous), neoplastic cells revealed clusterin reactivity characterized by a Golgi staining pattern. The proportion of reactive cells varied with more than 25% positive cells in the majority of cases. In 7 non-Hodgkin lymphomas of other types, fine cytoplasmic (3 cases) or strong membranous reactivity (4 cases) was observed for clusterin. In Hodgkin lymphoma, rare Reed-Sternberg cells exhibited focal cytoplasmic or membranous clusterin positivity. In the nonhematopoietic neoplasms, a Golgi staining pattern was apparent in only 2 cases, 1 lobular carcinoma of the breast and 1 poorly differentiated colonic carcinoma; however, cytoplasmic reactivity was noted in 12 of 30 carcinomas and 1 of 5 neuroendocrine neoplasms. A Golgi pattern of reactivity for clusterin seems highly characteristic of ALCL among hematopoietic neoplasms, but also might be observed in rare nonhematopoietic tumors, necessitating the use of a broad immunohistochemical panel for evaluation of poorly differentiated neoplasms of indeterminate derivation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15151211     DOI: 10.1309/GQ2R-LNDW-LB9W-Y6UU

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a Well-differentiated Tumor Suggests a Jejunoileal Origin.

Authors:  Thomas W Czeczok; Kristen M Stashek; Jessica E Maxwell; Thomas M O'Dorisio; James R Howe; Jason L Hornick; Andrew M Bellizzi
Journal:  Appl Immunohistochem Mol Morphol       Date:  2018-02

2.  Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma.

Authors:  Gabriela Gualco; Lawrence M Weiss; Carlos E Bacchi
Journal:  Hum Pathol       Date:  2008-07-11       Impact factor: 3.466

3.  Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy.

Authors:  Alessandra Ruggiero; Giuseppe Rubens Pascucci; Nicola Cotugno; Sara Domínguez-Rodríguez; Stefano Rinaldi; Alfredo Tagarro; Pablo Rojo; Caroline Foster; Alasdair Bamford; Anita De Rossi; Eleni Nastouli; Nigel Klein; Elena Morrocchi; Benoit Fatou; Kinga K Smolen; Al Ozonoff; Michela Di Pastena; Katherine Luzuriaga; Hanno Steen; Carlo Giaquinto; Philip Goulder; Paolo Rossi; Ofer Levy; Savita Pahwa; Paolo Palma
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

Review 4.  Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece.

Authors:  E Campo; A Chott; M C Kinney; L Leoncini; C J L M Meijer; C S Papadimitriou; M A Piris; H Stein; S H Swerdlow
Journal:  Histopathology       Date:  2006-04       Impact factor: 5.087

5.  CHN1 is a Novel Prognostic Marker for Diffuse Large B-Cell Lymphoma.

Authors:  Jie Sun; Xiaoquan Zhu; Yanyang Zhao; Qi Zhou; Ruomei Qi; Hui Liu
Journal:  Pharmgenomics Pers Med       Date:  2021-04-01

6.  Retrospective Case-Control Study of Apolipoprotein J/Clusterin Protein Expression in Early Liveborn Neonatal Deaths with and without Pontosubicular Necrosis.

Authors:  Kathreena M Kurian; Declan McGuone
Journal:  Patholog Res Int       Date:  2012-07-12

Review 7.  The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL).

Authors:  Ivonne A Montes-Mojarro; Julia Steinhilber; Irina Bonzheim; Leticia Quintanilla-Martinez; Falko Fend
Journal:  Cancers (Basel)       Date:  2018-04-04       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.